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ABSTRACT 
Combining the analysis of mutations with aberrant expression of genes previously 
related to poorer prognosis in both acute promyelocytic leukemia (APL) and acute 
myeloid leukemia, we proposed an integrative score in APL (ISAPL) and 
demonstrated its relationship with clinical outcomes of patients with APL treated 
with all-trans retinoic acid (ATRA) in combination with anthracycline-based 
chemotherapy. Based on FLT3-ITD mutational status, ΔNp73/TAp73 expression 
ratio, ID1 BAALC ERG and KMT2E gene expression levels, ISAPL was fully modeled 
in 159 patients (median ISAPL score: 3, range: 0-10). Early mortality (P<0.001), 
complete remission (P=0.004), overall survival (P<0.001), cumulative incidence of 
relapse (P=0.028), disease-free survival (P=0.03), and event-free survival 
(P<0.001) rates were significantly different between patients assigned to the low- 
and high-risk groups. In summary, ISAPL modeling identified two distinct groups 
of patients, with significant differences in remission achievement, relapse, and 
survival, therefore, may improve consolidation treatment stratification in APL 
patients treated with ATRA and anthracycline-based chemotherapy. 
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INTRODUCTION 
In the context of all-trans retinoic acid (ATRA) and anthracycline-based 
chemotherapy, heterogeneity of clinical outcomes of patients with acute 
promyelocytic leukemia (APL) may be higher than expected, mainly outside well-
controlled clinical trials.1–3 Although well-succeed initiatives, such as the 
International Consortium on Acute Promyelocytic Leukemia (IC-APL) study, has 
significantly improved the treatment outcomes of patients who live in low- and 
middle-income countries (LMIC),4 these results are still inferior to those reported 
by high-income countries (HIC),5 reinforcing the idea that the prognosis of APL is 
not as favorable as is frequently stated.  
Based on the results from clinical trials using arsenic trioxide associated 
with ATRA and minimal chemotherapy for those patients with high risk disease, it 
is conceivable that many factors associated with unfavorable prognosis as well as 
differences between the results of treatment in LMIC and HIC would be reduced.6–8 
However, most patients who live in LMIC does not benefit from these recent 
improvements, mainly because this compound is still not available in public 
healthcare programs. Therefore, at least for a near future, alternative strategies for 
predicting outcomes in patients treated with ATRA and chemotherapy should be 
tested. Here, we combined recurrent mutations with aberrant expression of genes 
previously associated with poor prognosis in both APL9–16 and acute myeloid 
leukemia (AML),17–21 and proposed an integrative score in APL (ISAPL) for 
outcomes prediction. 
 
DESIGN and METHODS 
Patients  
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Between October 2006 and June 2015, diagnostic bone marrow samples from 183 
adult patients with APL who were enrolled in the IC-APL study were analyzed. 
Details about the diagnosis, eligibility criteria and treatment protocol are 
published elsewhere.4 Written informed consent was obtained from all patients, 
following the Declaration of Helsinki recommendations. The local Research Ethics 
Board of each participating center approved the study.  
 
DNA extraction and screening for FLT3-ITD mutations 
Genomic DNA was extracted using the Puregene kit (Gentra System) according to 
the manufacturer’s protocol. Screening for the FLT3-ITD mutations was performed 
by PCR according to the method of Kiyoi et al,22 followed by electrophoresis on 3% 
agarose gel stained with ethidium bromide. Internal and external validations for 
FLT3-ITD mutations screening were described elsewhere.11 
 
Gene expression profile  
Real-time quantitative polymerase chain reactions assays using patient-derived 
cDNA were accomplished in duplicate on MicroAmp optical 96-well plates using a 
7500 Real-Time PCR System (Applied BioSystems). Transcript levels of TP73 
isoforms (TAp73, Assay ID: Hs00232088_m1; and ∆Np73 Assay ID: 
Hs01065727_m1, Applied BioSystems), KMT2E (Assay ID: Hs00218773_m1, 
Applied BioSystems) and BAALC genes (Assay ID: Hs00227249_m1, Applied 
BioSystems) were determined as previously described.9,10,15 Expression levels of 
ERG (Assay ID: Hs01554635_m1, Applied BioSystems), ID1 (Assay ID: 
Hs00357821_g1, Applied BioSystems), PIM2 (Assay ID: Hs00179139_m1, Applied 
BioSystems), PRAME (Assay ID: Hs01022301_m1, Applied BioSystems), and WT1 
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genes (Assay ID: Hs01103751_m1, Applied BioSystems) were determined using 
the TaqMan Gene Expression, following the manufacturer’s instructions. The 
comparative cycle threshold (Ct) method was used to determine the relative 
expression levels of ERG, ID1, PIM2, PRAME, and WT1 genes by using the ABL 
FusionQuant Standard Kit as endogenous control (Ipsogen). The gene expression 
profile was calculated relative to a reference cDNA (NB4 cell line) and results were 
expressed as 2-ΔΔCt. Details can be found elsewhere.9  
 
Dichotomization strategy and samples categorization  
Patients presenting with FLT3-ITD mutations were designated mutated, while 
patients without FLT3-ITD mutations were defined non-mutated. For continuous 
variable, we used two different strategies to define optimal cutoffs: first, we 
divided the total cohort into quartiles (Q) according to expression levels of each 
gene. Based on the survival curves (using overall survival as a primary parameter), 
quartiles with similar event probabilities were grouped. Next, we confirmed these 
findings using survival receiver operating characteristic (ROC) curve analysis23 
and the C index.24 Whether no cutoff could be evidenced by these two strategies, 
patients with expression values higher than the median were classified as having 
high expression. According to these criteria, patients were dichotomized at the 
median value of PIM2, and PRAME expression, lowest 25% expression of ERG and 
WT1 genes (i.e., those assigned to the first quartile, Q1) and highest 75% 
expression of ID1 gene (i.e., those assigned to the fourth quartile, Q4). The gene 
expression profile and dichotomization strategies for ∆Np73/TAp73 expression 
ratio, KMT2E, and BAALC gene were previously described.9,10,15  
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Statistical analysis and clinical endpoints 
Fisher’s exact test or Chi-square test, as appropriate, was used to compare 
categorical variables. Kruskal-Wallis test was used to compare continuous 
variables. Overall survival (OS), disease‐free survival (DFS) and event-free survival 
(EFS) were estimated using the Kaplan–Meier method. OS was defined as the time 
from diagnosis to death from any cause; those alive or lost to follow-up were 
censored at the date last known alive. Early mortality was defined as death 
occurring within 30 days from diagnosis. For patients who achieved CR, DFS was 
defined as the time from CR achievement to the first adverse event: relapse, 
development of secondary malignancy, or death from any cause, whichever 
occurred first. EFS was defined as the time from the initiation of induction therapy 
to disease relapse, development of secondary malignancy, or death from any cause, 
whichever occurred first. Patients who were alive without disease relapse or 
secondary malignancy were censored at the time they were last seen alive and 
disease‐free. The log‐rank test was used for comparisons of Kaplan–Meier curves. 
Cumulative incidence curves for non-relapse death and relapse with or without 
death were constructed to reflect time to relapse and time to non-relapse death as 
competing risks. Time to relapse and time to non-relapse death were measured 
from the date of CR.  
Univariable and multivariable logistic regression analyses were performed 
in order to identify prognostic factors for CR. Univariable and multivariable 
proportional hazards regression analysis was performed for potential prognostic 
factors for OS, DFS, and EFS. Potential prognostic factors examined and included in 
multivariable regression analysis were age at diagnosis (analyzed as a continuous 
variable), and initial leukocyte counts (analyzed as a continuous variable). 
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Proportional hazards assumption for each continuous variable of interest was 
tested. Linearity assumption for all continuous variables was examined in logistic 
and proportional hazards models using restricted cubic spline estimates of the 
relationship between the continuous variable and log relative hazard/risk. All P-
values were two-sided with a significance level of 0.05. All calculations were 
performed using Stata Statistic/Data Analysis version 12 (Stata Corporation), and 
R 3.3.2 (The CRAN project, www.r-project.org) software. 
 
Assignment of weights to prognostic markers  
Integer weights for the risk score were derived from Cox proportional hazard 
model, identical to that reported by Damm et al.,25 using OS as endpoint and 
including P-values lower than 0.05 in the model. Variables considered for the 
model inclusion were the following: FLT3-ITD status, gene expression profile of 
∆Np73/TAp73 ratio and transcript levels of KMT2E, BAALC, ID1, and ERG genes. 
Other candidates, such as PIM2, WT1, PRAME, and IDH1, were not associated with 
lower OS and not included in the score. Hazard ratios (HR) for OS were calculated 
for each variable separately. The HR was converted to integer weights according to 
the following: variables with HR  1 were excluded from analyses; variables with 
HR > 1 and  1.5 were assigned a weight of 1; variables with HR > 1.5 and  2.5 
were assigned a weight of 2; variables with HR > 2.5 were assigned a weight of 3. 
The final score was the sum of these integer weights. 
 
RESULTS 
ISAPL modeling in APL 
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Complete data for ISAPL modeling was available for 159 of 183 (87%) patients. 
The remaining 24 patients (13%) were not included in the score because biological 
material (DNA and/or RNA) was not available at diagnosis or due to lack of one or 
more genetic markers needed to compose the ISAPL in full. To test whether 
patients not included in the ISAPL model were missing at random, the OS was 
evaluated for patients with and without ISAPL data. Estimated 5-year OS rate did 
not differ between patients included (82%, 95% confidence interval, CI: 72-88%) 
and not included (90%, 95% CI: 78-95%) in the score (P=0.509). Univariable Cox 
proportional hazard analysis revealed that FLT3-ITD mutational status (hazard 
ratio, HR: 2.72, 95% confidence interval, CI: 1.2-6.22; P=0.018), high 
ΔNp73/TAp73 expression ratio (HR: 4.43, 95% CI: 1.83-10.7; P=0.001), high 
expression of ID1 (HR: 3.41, 95% CI: 1.42-8.22; P=0.006), and BAALC genes (HR: 
2.68, 95% CI: 1.04-6.92; P=0.041), and low expression of ERG (HR: 2.65, 95% CI: 
1.15-6.42; P=0.03) and KMT2E genes (HR: 3.26, 95% CI: 1.18-8.99; P=0.022) were 
associated with lower OS, and, therefore, were used to generate the ISAPL (Table 
1).  
 
Clinical and laboratory features 
According to the median value of ISAPL modeling (median value: 3, range: 0-10), 
we dichotomized patients into two groups (i.e., low-risk, < 3; high-risk, ≥ 3). 
Descriptive analyses were performed for patient baseline features (Table 2). The 
median age was 35 years (range: 18-82 years) with 82 males (44%). According to 
PETHEMA/GIMEMA criteria for predicting relapse,26 31% and 50% of patients 
assigned to the low- and high-risk groups were deemed high-risk patients, 
respectively (P=0.037). 




Patient follow-up was last updated in September 2018. Of the 183 subjects 
included in the study, 24 patients were lost to follow-up prior to the assessment of 
remission status and thus were not counted in the induction outcome analysis. 
Overall, 131/159 (82%) patients achieved complete hematological remission (CR). 
Of 28 patients (18%) who failed to achieve CR, 21 (75%) experienced early 
mortality (i.e., death within 30 days after diagnosis). The main causes of death 
during induction were hemorrhage (11 patients, 52%), followed by infection (nine 
patients, 43%) and central nervous system thrombosis (one patient, 5%). Early 
mortality was significantly higher in patients with high-risk (23%) than patients 
with low-risk (4%) (P<0.001). CR rates according to the ISAPL modeling were 91% 
and 73% for low- and high-risk, respectively (P=0.004). In univariate logistic 
regression analysis, ISAPL modeling was significantly associated with CR (odds 
ratio, OR: 0.26, 95% CI: 0.17-0.66; P=0.005). These results were consistent with 
multivariable analysis (OR: 0.23, 95% CI: 0.1-0.63; P=0.004), considering age, and 
leukocyte counts as confounders (Table 3). 
With a median follow-up time among survival of 32 months (range: 1-101 
months), the estimated 5-year OS rate was 78% (95% CI: 71–82%). Patients 
assigned to the high-risk group exhibited significantly lower 5-year OS rate (55%, 
95% CI: 40-68%) than patients assigned to the low-risk group (91%, 95% CI: 81-
95%) (P<0.001; Figure 1A). Cox proportional hazards modeling showed that ISAPL 
modeling was independently associated with poor OS (HR: 5.77, 95% CI: 2.33-8.27; 
P<0.001) (Table 3). 
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Post-remission outcomes 
Out of the 82 patients who achieved CR, nine patients (11%) relapsed at a median 
time of 43 days (range: 23-389 days). Considering non-relapse death as a 
competing cause of failure, the 5-year cumulative incidence of relapse (CIR) rate 
was 12% (95% CI: 7-17%). CIR rates for patients with low- and high-risk were 9% 
(95% CI: 2-17%) and 25% (95% CI: 11-39%) respectively (P=0.028; Figure 1B). 
The estimated 5-year DFS and EFS rates were 87% (95% CI: 80–92%), and 70% 
(95% CI: 63-76%), respectively. Patients with high ISAPL score had a significantly 
lower DFS rate (71%, 95% CI: 53-84%) in comparison to patients with low score 
(90%, 95% CI: 80-95%) (P=0.03; Figure 1C). This result was consistent with the 
multivariable proportional hazards analysis (HR: 2.25, 95% CI: 1.8-6.29; P=0.012) 
(Table 3). In agreement, EFS rate was significantly lower in high-risk patients 
(45%, 95% CI: 31-58%) than those with low-risk (83%, 95% CI: 72-90%) 
(P<0.001; Figure 1D). Accordingly, ISAPL modeling was associated with shorter 
EFS in an independent manner (HR: 3.97, 95% CI: 1.98-7.97; P<0.001) (Table 3). 
 
DISCUSSION 
We and others have previously demonstrated that a relatively large set of genes 
are aberrantly expressed or frequently mutated in APL. Most important, these 
genetic findings may be prognostically relevant in a clinical setting in which ATRA 
and anthracycline-based chemotherapy constitute the basis for induction 
trearapy.9–11,15,27–30 Here, we hypothesized that if these molecular prognostic 
markers were pooled together into a single prognostic risk score, the resulting 
information could be more accurate than focus on a single molecular marker at a 
time. Such approach has been already demonstrated in both AML non-APL25,31–33 
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and myelodysplastic syndromes,34 although score systems for prognosis prediction 
in APL have not been explored in the same extent. To the best of our knowledge, 
the first study to propose a molecular risk score in APL was reported by Hecht et 
al.. Although the sample size was limited (79 patients), the authors demonstrated 
that BAALC, ERG and WT1 expression levels integrated into a score could be a 
promising approach to guide monitoring of patients with APL treated with ATRA 
and high doses of cytarabine.35,36 Here, we and extended this panel and 
demonstrated that gene mutations and aberrant gene expression combined could 
be a useful tool to robustly improve outcomes prediction in patients with APL, at 
least for those treated with ATRA in combination with chemotherapy. Our ISAPL 
modeling has resulted in the separation of two distinct groups of patients, with 
significant differences for remission achievement, relapse and survival.  
Despite the promising results, other issues should be taken into 
consideration for molecular monitoring purposes in APL, including validation data 
in independent cohorts, the establishment of universal controls, and cut-off values 
that uniformly defined in studies. Furthermore, considering time from diagnosis to 
treatment initiation as one of the most important steps in attaining success in 
induction therapy in acute leukemias, one may argue if the ISAPL modeling or 
others schemes for APL risk stratification35 could be available to the medical team 
soon after diagnosis. In our experience, with proper infrastructure and skilled 
labor, a reference laboratory would be able to conclude all genetic markers for 
ISPAL modeling within 24-48 hours. Moreover, the progressive decreasing in 
sequencing costs and the relative facility to obtain high quality of gene 
quantification in a high number of samples suggest that, in a near future, such 
strategy will become more accessible and could be incorporated into the clinical 
Commented [dM2]: Acho desnecessário, embora o Calado 
tenha questionado no Hemo. Acredito que começar pelo 
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practice, even in countries with socioeconomic heterogeneity and limited 
resources, as Brazil.  
Here, we included nine genetic markers previously associated with 
prognosis in both APL and AML to compose the ISAPL modeling. Part of these 
candidates was functionally evaluated by us37 and others38–40 in order to 
understand the biological significance described in the clinical setting. Previously, 
we demonstrated that ΔNp73 exerted an important role in cell survival, providing 
resistance to drug-induced apoptosis.41 Following the same experimental strategy, 
several studies have demonstrated that FLT3-ITD mutations, overexpression of 
BAALC, PIM2 in the cooperation in the induction of a leukemic phenotype. In an 
APL context, unpublished data from our group strongly suggest that the 
overexpression of KMT2E, BAALC, and ΔNp73 in both in vitro (using NB4/NB4-R2 
cell lines as target cells) and in vivo (through murine bone marrow cells 
transplantation model from hCG-PML/RARA transgenic mice) are able to modulate 
granulocytic differentiation pathways and directly act in the responsiveness of APL 
leukemic cells to ATRA therapy. Moreover, standardized assays are already 
available for prognostication of patients with intermediate cytogenetic risk acute 
myeloid leukemia are current using some of these genetic markers in the clinical 
practice.42  
We acknowledge that our modeling or any other prognostic risk score in 
APL could become clinically irrelevant if the frontline ATO-ATRA combination is as 
effective as recent clinical trials have been demonstrating.6–8 If this efficacy is 
proven, ATO-ATRA treatment may overcome diagnostic characteristics previously 
associated with adverse outcomes in APL,43 with great benefits for patients. 
Nevertheless, as we mentioned in previous studies, the most important reasons for 
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ATRA-ATO combination does not constitute the therapy of choice for patients with 
APL in Latin America are due to its low availability in most reference centers and 
higher cost for the public healthcare system.15 Since ATRA plus chemotherapy still 
constitutes the basis for APL treatment in most LMIC and, apparently, this scenario 
may endure for some years to come, we believe that our scheme for risk 
stratification represents a viable alternative for identifying patients who need a 
closer follow-up. 
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Table 1. Variables used for the determination of the integrated score in APL (ISAPL). 
Variables analyzed Dichotomization strategy 
Learning set  
Cox proportional hazard modeling Integer 
weight1 HR (95% CI); P-value 
FLT3-ITD status: mutated vs non-mutated Not applicable 2.72 (1.2 to 6.22); 0.018 3 
KMT2E gene expression: low vs high Q1-Q2 vs Q3-Q4 3.26(1.18 to 8.99); 0.022 2 
BAALC gene expression: high vs low Q3-Q4 vs Q1-Q2 2.68 (1.04 to 6.92); 0.041 2 
ΔNp73/TAp73 ratio: high vs low Q4 vs Q1-Q3 4.43 (1.83 to 10.7); 0.001 3 
ID1 gene expression: high vs low Q4 vs Q1-Q3 3.41 (1.42 to 8.22); 0.006 2 
ERG gene expression: low vs high Q1 vs Q2-Q4 2.65 (1.15 to 6.42); 0.03 3 
WT1 gene expression: low vs high  Q1 vs Q2-Q4 6.78 (0.9 to 50.7); 0.061 - 
PRAME gene expression: high vs low Q3-Q4 vs Q1-Q2 1.02 (0.42 to 2.45); 0.96 - 
PIM2 gene expression: high vs low Q3-Q4 vs Q1-Q2 1.23 (0.5 to 2.96); 0.644 - 
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Table 2. Baseline characteristics. 
  ISPAL modeling  
Characteristics 
All patients Low-risk High-risk 
P-value1 
No. % Median (range) No. % Median (range) No. % Median (range) 
Gender          0.008* 
 Female 101 55.2  61 64.9  40 44.9   
 Male 82 44.8  33 35.1  49 55.1   
Age, years   35.6 (18.3, 82.5)   37.7 (18.3, 82.5)   34.9 (18.4, 66.5) 0.517 
 18-40 89 56.7  44 55.7  45 57.7   
 41-60 56 35.7  26 32.9  30 38.5   
 ≥60 13 7.6  9 11.4  3 3.8   
 Unknown 25 -  15 -  11 -   
ECOG performance status          0.483 
 0 78 54.5  40 55.6  38 53.5   
 1 33 23.1  16 22.2  17 23.9   
 2 14 9.8  9 12.5  5 7   
 ≥3 18 12.6  7 9.7  11 15.5   
 Unknown 40 -  22 -  18    
Leukocyte counts, ×109/L   5.37 (0.8, 128.5)   3..4 (0.22, 102.7)   9.9 (0.8, 128.5) 0.027* 
 <5 77 48.7  45 56.3  32 41   
 5-10 17 10.8  10 12.5  7 9   
 10-50 47 29.7  20 25  27 34.6   
 ≥50 17 10.8  5 6.3  12 15.4   
 Unknown 25 -  14 -  11 -   
Platelet counts, ×109/L   25.5 (7, 230)   26 (4, 230)   25 (7, 157) 0.314 
 <40 123 77.8  59 73.8  64 82.1   
 ≥40 35 22.2  21 26.3  14 17.9   
 Unknown 25 -  14 -  11 -   
Relapse-risk group          0.037* 
 Low risk 24 15.2  16 20  8 10.3   
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 Intermediate risk 70 44.3  39 48.8  31 39.7   
 High risk 64 40.5  25 31.2  39 50   
 Unknown 25 -  14 -  11 -   
Hemoglobin, g/dL   8.7 (3.2, 21.8)   8.6 (3.4, 21.8)   8.7 (3.2, 14.9) 0.939 
 <10 118 74.7  57 71.3  61 78.2   
 ≥10 40 25.3  23 28.7  17 21.8   
 Missing 25 -  14 -  11 -   
Creatinine, mg/dL   0.8 (0.8, 4.3)   0.8 (0.4, 2.8)   0.81 (0.4, 4.3) 0.48 
 <1.4 146 94.8  78 98.7  68 90.7   
 ≥1.4 8 5.2  1 9.6  7 9.3   
 Unknown 29 -  15 -  14 -   
Uric acid, mg/dL   3.9 (1.1, 10.3)   3.8 (1.1, 8.1)   4.1 (2, 10.3) 0.227 
 <7 132 89.8  66 90.4  66 89.2   
 ≥7 15 10.2  7 9.6  8 10.8   
 Unknown 36 -  21 -  15 -   
Fibrinogen (mg/dL)   160 (10, 898)   163 (10, 898)   159 (0.5, 549) 0.86 
 <170 80 53.7  40 52.6  40 54.8   
 ≥170 69 46.3  36 47.4  33 45.2   
 Unknown 34 -  18 -  16 -   
Albumin (g/dL)   3.9 (2.2, 5.42)   3.9 (2.2, 5.42)   3.9 (2,4, 5) 0.754 
 <3.5 27 22.3  12 20  15 24.6   
 ≥3.5 94 77.7  48 80  46 75.4   
 Unknown 62   34 -  28 -   
Morphologic subtype          0.328 
 Hypergranular 148 93.7  76 96.2  72 91.1   
 Microgranular 10 6.3  3 3.8  7 8.9   
 Unknown 25 -  15 -  10 -   
PML breakpoint          0.383 
 BCR1 76 62.3  40 62.5  36 62.1   
 BCR2 2 1.6  2 3.1  22 37.9   
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 BCR3 44 36.1  22 34.4  58    
 Unknown 61 -  30 -  31 -   
NOTE: * Indicate differences statistically significant. 
1: Missing values were excluded in the calculation of P-values. 
2: Classification according to PETHEMA-GIMEMA criteria. (PMID: 10942364) 
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Table 3. Univariable and multivariable. 
End point Model Variables 
Univariable Analysis Multivariable Analysis 
HR OR 95% CI P -value HR OR 95% CI P-value 
CR ISAPL modeling: low vs high  0.26 0.17 0.66 0.002  0.23 0.1 0.63 0.004 
Leukocyte counts (×109/L): continuous variable  0.57 0.34 0.96 0.036  0.9 0.47 1.73 0.771 
Age at diagnosis: continuous variable  0.4 0.2 0.79 0.008  0.7 0.42 1.15 0.164 
OS ISAPL modeling: low vs high 5.1  2.22 11.6 <0.001 5.77  2.33 8.27 <0.001 
Leukocyte counts (×109/L): continuous variable 2.86  1.75 4.66 <0.001 1.92  1.1 3.44 0.027 
Age at diagnosis: continuous variable 1.5  1.05 2.26 0.047 2.34  1.35 4.08 0.002 
DFS ISAPL modeling: low vs high 2.86  1.1 7.88 0.04 2.25  1.8 6.29 0.012 
Leukocyte counts (×109/L): continuous variable 3.25  1.51 7 0.003 2.87  1.14 7.24 0.025 
Age at diagnosis: continuous variable 1.14  0.57 2.28 0.704 1.11  0.44 2.77 0.816 
EFS ISAPL modeling: low vs high 3.96  2.05 7.65 <0.001 3.97  1.98 7.97 <0.001 
Leukocyte counts (×109/L): continuous variable 2.69  1.77 4.1 <0.001 1.94  1.17 3.19 0.009 
Age at diagnosis: continuous variable 1.34  0.93 1.93 0.105 1.78  1.1 2.88 0.019 
NOTE. Hazard ratios (HRs) or odds ratios (ORs) > 1 or < 1 indicate an increased or decreased risk, respectively, of an event for the first 
category listed. 
Abbreviations: CR, complete remission; OS, overall survival; DFS, disease-free survival; EFS, event-free survival; HR, hazard ratio; OR, 
odds ratio.  
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FIGURE LEGENDS 
Figure 1. Patient survival. The probability of overall survival (A), cumulative 
incidence of relapse (B), disease-free survival (C) and event-free survival (D) in 
patients with acute promyelocytic leukemia (APL) according to ISAPL modeling. 
